A Phase 1a Study of LY4101174 in People With Bladder or Prostate Cancer


Full Title

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors


Researchers want to find the best dose of the antibody-drug conjugate LY4101174 to treat advanced bladder and prostate cancers. The people in this study have bladder or prostate cancer that came back or keeps growing after treatment. 

LY4101174 targets cells that have Nectin-4, a protein which plays a role in cancer cell growth. By destroying these cells, LY4101174 may help slow or stop the growth of your cancer. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have urothelial (bladder) or prostate cancer that has spread and keeps growing after treatment.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Jonathan Rosenberg’s office at 646-422-4461.




Phase I (phase 1)



ClinicalTrials.gov ID